Effects of Psilocybin in Major Depressive Disorder

Randomised, parallel-group trial comparing immediate versus 8‑week delayed psilocybin treatment in adults with major depressive disorder; participants receive two oral dosing sessions (first session moderately high, second session moderately high or high).

Primary outcome (GRID-HAMD) assessed by blinded raters. Secondary assessments include mood, attitudes, behaviours and safety measures; concurrent stable psychotherapy allowed.